About the API
Carbidopa, classified as a non-competitive decarboxylase inhibitor, is used in combination with the chemically related levodopa for the treatment of Parkinson’s disease or Parkinson-like symptoms (e.g. stiffness, shakiness, difficulty moving). Used alone, carbidopa has no effect on Parkinson’s symptoms. It is used to improve the effect of levodopa and reduce unwelcome side effects such as nausea. The drug works by preventing the breakdown of levodopa in the bloodstream, which allows more levodopa to enter the brain. Carbidopa has no anti-Parkinson effects by itself.
Presently, carbidopa is prepared by large-scale semi-synthetic methods. Semi-synthesis is a type of chemical synthesis that makes use of compounds derived from natural sources (bacterial; cell cultures; plant material) as starting material. Levodopa, a semi-synthetic product itself, can be easily converted to carbidopa in a single step.